Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients

John M. Pagel, Stephen Spurgeon, John C. Byrd, Farrukh T. Awan, Ian W. Flinn, Mark C. Lanasa, Amy J. Eisenfeld, Scott C. Stromatt, Ajay K. Gopal

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. Patients with relapsed or refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) received otlertuzumab at 20 mg/kg administered intravenously once a week for up to 8 weeks followed by 4 monthly doses. Sixteen patients were treated; median age was 62·5 years (range, 41-81), and median number of prior regimens was 4 (range, 1-7). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half-life was 9·5 days. Lymph node reduction of ≥50% by computerized tomography scan measurements was seen in 3 of 12 patients, including one FL patient who had a partial response. One WM patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma patients. These data suggest that further clinical investigation in non-Hodgkin lymphoma is warranted.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalBritish Journal of Haematology
Volume168
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Proteins
Non-Hodgkin's Lymphoma
Waldenstrom Macroglobulinemia
Therapeutics
Mantle-Cell Lymphoma
Follicular Lymphoma
TRU 016
B-Cell Lymphoma
Neutropenia
Thrombocytopenia
Nausea
Fatigue
Half-Life
Diarrhea
Edema
B-Lymphocytes
Lymph Nodes
Tomography

Keywords

  • AntiCD37
  • Clinical trial
  • Non-Hodgkin lymphoma
  • Otlertuzumab

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients. / Pagel, John M.; Spurgeon, Stephen; Byrd, John C.; Awan, Farrukh T.; Flinn, Ian W.; Lanasa, Mark C.; Eisenfeld, Amy J.; Stromatt, Scott C.; Gopal, Ajay K.

In: British Journal of Haematology, Vol. 168, No. 1, 01.01.2015, p. 38-45.

Research output: Contribution to journalArticle

Pagel, JM, Spurgeon, S, Byrd, JC, Awan, FT, Flinn, IW, Lanasa, MC, Eisenfeld, AJ, Stromatt, SC & Gopal, AK 2015, 'Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients', British Journal of Haematology, vol. 168, no. 1, pp. 38-45. https://doi.org/10.1111/bjh.13099
Pagel, John M. ; Spurgeon, Stephen ; Byrd, John C. ; Awan, Farrukh T. ; Flinn, Ian W. ; Lanasa, Mark C. ; Eisenfeld, Amy J. ; Stromatt, Scott C. ; Gopal, Ajay K. / Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients. In: British Journal of Haematology. 2015 ; Vol. 168, No. 1. pp. 38-45.
@article{15ceb8f9720a4f01bc234119d4aa6556,
title = "Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients",
abstract = "CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. Patients with relapsed or refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenstr{\"o}m's macroglobulinaemia (WM) received otlertuzumab at 20 mg/kg administered intravenously once a week for up to 8 weeks followed by 4 monthly doses. Sixteen patients were treated; median age was 62·5 years (range, 41-81), and median number of prior regimens was 4 (range, 1-7). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half-life was 9·5 days. Lymph node reduction of ≥50{\%} by computerized tomography scan measurements was seen in 3 of 12 patients, including one FL patient who had a partial response. One WM patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma patients. These data suggest that further clinical investigation in non-Hodgkin lymphoma is warranted.",
keywords = "AntiCD37, Clinical trial, Non-Hodgkin lymphoma, Otlertuzumab",
author = "Pagel, {John M.} and Stephen Spurgeon and Byrd, {John C.} and Awan, {Farrukh T.} and Flinn, {Ian W.} and Lanasa, {Mark C.} and Eisenfeld, {Amy J.} and Stromatt, {Scott C.} and Gopal, {Ajay K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/bjh.13099",
language = "English (US)",
volume = "168",
pages = "38--45",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients

AU - Pagel, John M.

AU - Spurgeon, Stephen

AU - Byrd, John C.

AU - Awan, Farrukh T.

AU - Flinn, Ian W.

AU - Lanasa, Mark C.

AU - Eisenfeld, Amy J.

AU - Stromatt, Scott C.

AU - Gopal, Ajay K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. Patients with relapsed or refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) received otlertuzumab at 20 mg/kg administered intravenously once a week for up to 8 weeks followed by 4 monthly doses. Sixteen patients were treated; median age was 62·5 years (range, 41-81), and median number of prior regimens was 4 (range, 1-7). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half-life was 9·5 days. Lymph node reduction of ≥50% by computerized tomography scan measurements was seen in 3 of 12 patients, including one FL patient who had a partial response. One WM patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma patients. These data suggest that further clinical investigation in non-Hodgkin lymphoma is warranted.

AB - CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. Patients with relapsed or refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) received otlertuzumab at 20 mg/kg administered intravenously once a week for up to 8 weeks followed by 4 monthly doses. Sixteen patients were treated; median age was 62·5 years (range, 41-81), and median number of prior regimens was 4 (range, 1-7). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half-life was 9·5 days. Lymph node reduction of ≥50% by computerized tomography scan measurements was seen in 3 of 12 patients, including one FL patient who had a partial response. One WM patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma patients. These data suggest that further clinical investigation in non-Hodgkin lymphoma is warranted.

KW - AntiCD37

KW - Clinical trial

KW - Non-Hodgkin lymphoma

KW - Otlertuzumab

UR - http://www.scopus.com/inward/record.url?scp=84915788744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915788744&partnerID=8YFLogxK

U2 - 10.1111/bjh.13099

DO - 10.1111/bjh.13099

M3 - Article

VL - 168

SP - 38

EP - 45

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -